Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization’s (WHO) Therapeu
Medtronic plc (NYSE:MDT) is one of the best healthcare stocks to buy with highest upside potential. On May 21, Goldman Sachs reinstated coverage of Medtronic plc (NYSE:MDT) with a Neutral rating and set a $84 price target on the stock, which offers 7.5% upside potential</p
Analysts see LLY reaching $1,500 within a year after 19% weight-loss data and four consecutive EPS beats boosted shares to 52-week highs. Eli Lilly shares surged to a 52-week high after retatrutide delivered 19% weight-loss results in Phase 3 trials, outpacing AstraZeneca’
TMC secures regulatory approval to explore 122,000 square kilometers for polymetallic nodules containing critical minerals. The National Oceanic and Atmospheric Administration approved TMC The Metals Company’s expanded exploration license for deep-sea mining in the Pacific
Goldman Sachs identifies two newly public stocks down at least 18% from IPO prices as compelling buys amid rising issuance activity. Goldman Sachs analysts have highlighted two recently listed stocks trading at least 18% below their debut prices as attractive entry points.
AVGO shares fell sharply after reporting $22.19 billion in revenue and $10.8 billion in AI semiconductor sales, missing market expectations. Broadcom reported fiscal Q2 revenue of $22.19 billion, up 47.9% year over year, with AI semiconductor revenue surging 143% to $10.8
Boston Scientific sees price targets cut to $61 and $68 by TD Cowen and BofA amid broader medtech sector valuation pressures. TD Cowen reduced Boston Scientific’s price target to $61 from $80 on May 29, maintaining a Buy rating but adjusting for updated Watchman data and o
Barclays reduced Medline's price target amid inflationary pressures and near-term valuation concerns while maintaining an Overweight rating. Barclays lowered its price target for Medline Inc. (NASDAQ:MDLN) to $45 from $50, citing inflationary pressures on margins and reduc
Zoetis faces downgrades and a lowered price target as analysts cite intensifying competition and investor confidence concerns. Stifel reduced Zoetis Inc. (ZTS) price target to $95 from $105 while maintaining a Hold rating, citing near-term competitive pressures despite imp
Mizuho increased Arm Holdings' price target citing accelerating agentic AI tailwinds and expanded partnerships with Oracle and ByteDance. Mizuho lifted Arm Holdings' (NASDAQ:ARM) price target to $500 from $425, maintaining an Outperform rating. The firm highlighted acceler
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.